RxCAP, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RxCAP, Inc. - overview
Established
2019
Location
Lynnfield, MA, US
Primary Industry
Healthcare IT
About
Based in Massachusetts, US, and founded in 2019 by Sreeram Ramakrishnan, RxCAP, Inc. operates as a provider of remote monitoring solutions to healthcare organizations, providing modular software, APIs, and medication adherence technology. In April 2024, RxCAP, Inc. raised USD 19.
66 million in Series B funding from unspecified investors. As of 2024, the company is led by its CEO, Sreeram Ramakrishnan. The company provides a remote patient monitoring platform that offers prescription adherence technology to pharmacies, payers, providers, pharmaceutical companies, and clinical research organizations. The platform services include the RPM enablement platform and APIs, software, proprietary hardware, analytics, and remote monitoring kits.
Moreover, the firm offers solutions such as building and shipping device kits to patients. Additionally, the company also provides services such as integrating APIs into existing systems and caregiver monitoring of device activity.
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT, Medical Equipment Distributors, Monitoring Equipment, Application Integration Software, Medical Software
Website
https://rxcap.com/
Verticals
Cloud Computing
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.